Clinical Trials Browser

Smoldering Multiple Myeloma × selinexor × Clear all

NCT05597345 2025-02-10

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Phase 2 Recruiting

Smoldering Multiple Myeloma, Multiple Myeloma, Neoplasms, Plasma Cell